meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab plus ipilimumab
title
nivolumab alone
title
NRG GY003, 2020 NCT02498600 metastatic/advanced OC (mOC) - 2nd line (L2) 49/51
Pathology:
metastatic/advanced OC (mOC) - 2nd line (L2);
metastatic/advanced OC (mOC) - 2nd line (L2)
NRG GY003, 2020
nivolumab plus ipilimumab
1
T1
nivolumab alone
0
T0